Regression of common viral warts in an immunocompetent child and an immunosuppressed adult relative after mRNA BNT162b2 COVID-19 vaccine
- PMID: 36148591
- PMCID: PMC9538617
- DOI: 10.1111/jdv.18577
Regression of common viral warts in an immunocompetent child and an immunosuppressed adult relative after mRNA BNT162b2 COVID-19 vaccine
Comment in
-
Editor's Picks February 2023.J Eur Acad Dermatol Venereol. 2023 Feb;37(2):215-216. doi: 10.1111/jdv.18817. J Eur Acad Dermatol Venereol. 2023. PMID: 36640376 No abstract available.
References
REFERENCES
-
- Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078-90.
-
- Gambichler T, Boms S, Hessam S, Tischoff I, Tannapfel A, Lüttringhaus T, et al. Primary cutaneous anaplastic large-cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination. Br J Dermatol. 2021;185:1259-62.
-
- Lynch MD, Cliffe J, Morris-Jones R. Management of cutaneous viral warts. BMJ. 2014;348:g3339.
-
- Pham CT, Juhasz M, Sung CT, Mesinkovska NA. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: a literature review. J Am Acad Dermatol. 2020;82:202-12.
-
- Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014;171:696-712.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
